

REMARKS

In response to the restriction requirement mailed September 3, 2008 applicants elect the Group 3 claims 12, 15-25, wherein the inhibitor of CSF-1 activity is an antibody. This election is made without traverse. Accordingly, claims 13 and 14 are now withdrawn from consideration.

The Examiner cites U.S. 5,932,595 at col. 2, 7th paragraph, as stating that “inhibition of proteins such as M-CSF would be a benefit in a number of disease states including inflammatory bowel disease.” Applicant notes that the cited portion of the reference states “... MMP inhibitors have also been shown to inhibit the release of other biologically active molecules from cells, including ... M-CSF. Inhibition of the *release or shedding* of such proteins may be of benefit in a number of disease states, including ... inflammatory bowel disease....” (emphasis added). Thus the reference states that it is the inhibition of the release of the proteins, rather than the inhibition of any one of the proteins themselves, that can benefit the disease state.

The Examiner has required restriction between claims 21 and 22, directed to treatment of different inflammatory bowel diseases. Applicant elects claim 21 directed to the treatment of Crohn’s disease, and claim 22 is now withdrawn from consideration.

The Examiner has required restriction between claims 24 and 25 directed to two different secondary agents. Applicant elects claim 24 directed to the secondary agent being another IBD-therapeutic agent, and claim 25 is now withdrawn from consideration.

The Examiner has required restriction between claims 19 and 20 directed to two different antibodies. Applicant elects claim 19 directed to the antibody being CSF-1, and claim 20 is now withdrawn from consideration.

Each of the foregoing elections is made without traverse.

The Examiner has required an election of species between the named antibodies and antibody fragments of claims 16-17. Applicant elects the species of the humanized antibody recited in claim 16, it being understood that the other species recited in claims 16 and 17 will be entitled to consideration upon allowance of a generic claim. Accordingly, claim 16 has been amended to recite only the elected species, and claim 17

is now withdrawn from consideration. It is respectfully submitted that all claims remaining in the application are readable on the elected species.

The Applicants invite the Examiner to contact the Applicants' undersigned representative at (312) 913-3362 if the Examiner believes that this would expedite prosecution of this application.

Respectfully submitted,

Date: October 3, 2008

By: /Sandra B. Weiss/

Sandra B. Weiss
Reg. No. 30,814

McDonnell Boehnen Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-3362